Since 2009, the Medical Technologies IKC has focused on advancing class three devices and regenerative devices for treatment of musculoskeletal disease, advanced wound care products, dental interventions and cardiovascular devices and grafts. It has also supported the research and development of enabling and companion technologies.
The global value of these market segments is currently £60bn, predicted to grow to £90bn by 2025. The growth in these market segments will involve increasing convergence of different and diverse technologies (including e.g. digital, advanced materials, AI and data analytics), which will be integrated into more sophisticated and innovative medical products, devices, services and systems. These diverse technologies will emerge from the research community, from health-tech industry and from other sectors.
New technology opportunities are emerging from universities, industry and from other sectors and being exploited by new start-ups, spin-outs and existing medical device companies.
The Medical Technologies IKC is making a significant contribution to this industry. Our main objective is to secure investment from the private sector to develop these technologies. By helping companies access knowledge, capability and people, and by facilitating clinical collaborations, we can help bridge the gap between fundamental research and the development of technology that’s fit for purpose and ready for serious industrial investment. Through our proof of concept projects and our strategic collaborations, we aim to reduce risk and uncertainty for companies, allowing them to invest with greater certainty to progress a technology beyond the validation stage all the way through to launch and subsequent commercial viability.